



BARR PHARMACEUTICALS NOTICE OF PRICE ADJUSTMENT TO PHS COVERED ENTITIES (updated contact information)

As part of its ongoing compliance efforts, Barr Pharmaceuticals, Inc. (“Barr”) is adjusting certain prices charged by its subsidiaries, Barr Laboratories, Inc., Duramed Pharmaceuticals, Inc. (formerly known as Finishing Enterprises Inc. Women’s Health and now known as Teva Women’s Health), and PLIVA d.d. for affected products bearing labeler codes 005555, 51285, 50907, and 50111 for the period from the fourth quarter of 2004 through the third quarter of 2009. The need for the adjustment results from Barr’s recalculation of average manufacturer prices and best prices reported to CMS under the Medicaid Drug Rebate Program for the same period. Barr will refund each PHS Covered Entity the amount of all identified overcharges. The refunds will not be reduced by the amount that any Covered Entity was inadvertently undercharged.

Barr has identified the Covered Entities that were overcharged and will contact them by U.S. mail during the month of March 2013 and distribute refunds as follows:

- **Covered Entities Due Refunds in Excess of \$500:** In an initial mailing, Barr will notify those Covered Entities that were overcharged by more than \$500.00 about the refund and request a W-9 form from them. If after 30 days, Barr does not receive the required W-9 form, it will send a second mailing asking for the form. If Barr does not receive a response from this mailing within 30 days, it will issue the refund check to the Covered Entity with the required tax deductions.
- **Covered Entities Due Refunds of \$500 or Less:** The initial mailing to Covered Entities with incurred overcharges of \$500 or less will include a check for the full amount of the identified overcharges.

Barr also will issue refunds to any Covered Entity that is not contacted by the company initially provided the Covered Entity can document that it purchased a Barr product subject to an overcharge during the relevant period and that it was a qualified Covered Entity enrolled in the 340B Program at the time of the purchase.

Covered Entities that wish to inquire about this refund program should contact:

Keya Williams, 1090 Horsham Road North Wales, PA, 19454 (215) 591-3042 EMAIL: Keya.Williams@tevapharm.com